Janssen Research & Development reported major results from the MajesTEC-9 Phase I/IIa trial of teclistamab in refractory multiple myeloma. In the study’s reported interim outcomes, teclistamab met its primary endpoint, improving progression-free and overall survival compared with control therapies. The company highlighted response depth, including high complete response rates and a substantial share of patients reaching minimal residual disease (MRD) negativity. MRD negativity is widely used as a marker of deep clearance in multiple myeloma and has been correlated with long-term outcomes. With nearly 600 patients included in the cohort, the results reinforce the rapid expansion of T-cell engaging strategies in myeloma treatment and fuel expectations for next steps in late-stage confirmatory development and label expansion.